Unknown Title

Key Concepts

• Nancy Pelosi’s Trading Activity: Analysis of recent stock disclosures and investment strategies of Nancy Pelosi and her husband.
• AI & Tech Sector Focus: Significant investments in AI-driven companies and established tech giants.
• Defensive Investing: Diversification into stable, dividend-paying assets.
• Vistra Corp (VST): Utility company positioned to benefit from the increasing energy demands of AI data centers.
• Serena Therapeutics (SERA): Biotechnology company developing a novel treatment for Parkinson’s disease.
• 505(b)(2) Pathway: FDA regulatory pathway for drug approval leveraging existing data.
• Parkinson’s Disease Treatment: Focus on improving delivery methods for Apomorphine, a dopamine agonist.

Pelosi’s Recent Investment Moves: A Deep Dive

This analysis details the recent investment activity of Nancy Pelosi, focusing on five significant trades disclosed in her latest filings. The speaker’s portfolio consistently outperforms market averages, prompting some investors to track her trades via ETFs. Unlike Warren Buffett, Pelosi’s trades often precede major announcements, regulatory changes, and policy shifts, suggesting potential access to non-public information.

5. Tempest AI (TEM) – AI-Driven Healthcare Diagnostics

Pelosi has been accumulating shares in Tempest AI since early 2025. Tempest is a small-cap company utilizing artificial intelligence to analyze medical data (genomic info, lab results, clinical records) for personalized cancer treatment. Their business model centers on selling AI tools to hospitals and research labs, and partnering with pharmaceutical companies to accelerate drug discovery. The timing of her initial investment coincided with a groundbreaking AI health app announcement from Tempest, resulting in a 300% jump in call option value. In 2026, Pelosi exercised options to acquire approximately 5,000 shares, signaling continued bullish sentiment. Her connections within the healthcare sector and potential awareness of favorable regulatory treatment for AI diagnostics are speculated as driving factors.

4. Apple (AAPL) – Reloading on an AI Play

Despite selling 45,000 shares and donating 28,200 shares (likely for tax benefits), Pelosi’s actions with Apple are interpreted as a strategic reload rather than an exit. Immediately following the sale, she purchased call options with a $100 strike price expiring in January 2027. This indicates a bet on an iPhone super cycle driven by AI integration, particularly the upgrade to Siri powered by Google’s Gemini backend. Her 2022 visit to Taiwan provided direct insight into US-China trade negotiations, informing her understanding of Apple’s supply chain diversification. Despite China-related stock dips, Pelosi continued to invest, suggesting confidence in Apple’s long-term prospects.

3. Alphabet (GOOGL) – Dominance in Tech & Antitrust Considerations

Pelosi continues to hold a substantial position in Alphabet (approximately 14% of her portfolio). She recently exercised calls, donated shares (potentially for tax benefits), and rolled into new January 2027 options with a $150 strike price. Her continued investment reflects a belief in the enduring dominance of big tech and a skepticism towards significant antitrust enforcement. Despite ongoing DOJ lawsuits and Congressional hearings, she anticipates Alphabet will maintain its position. Furthermore, she likely possesses inside knowledge regarding Google Cloud’s pursuit of federal contracts and AI research partnerships.

2. Alliance Bernstein (AB) – Defensive Positioning & Income

This trade represents a departure from Pelosi’s typical high-growth tech investments. Alliance Bernstein is a global asset management firm offering a dividend yield around 8%. Pelosi purchased 25,000 shares outright, representing a $1.5 million investment. This is interpreted as a defensive move, seeking income and stability after years of concentrated tech exposure. Her potential access to Federal Reserve briefings and insights into the company’s capital allocation strategies may have informed this decision.

1. Vistra Corp (VST) – The AI Energy Backbone

Vistra Corp, a utility company providing electricity and natural gas to 5 million customers, is positioned to benefit from the exponential energy demands of AI data centers. Pelosi purchased Vistra calls in early 2025, exercising them in January 2026 for 5,000 shares. This timing coincided with Vistra securing a 20-year power purchase agreement with Meta, guaranteeing 2,600 megawatts from three nuclear plants to power Meta’s AI data centers in Pennsylvania and Ohio. This deal likely required regulatory approval, potentially providing Pelosi with advance knowledge. Her investment reflects a recognition that the real “gold rush” lies in the infrastructure supporting AI, not just the AI startups themselves. Vistra’s nuclear energy capacity provides reliable, 24/7 base load power essential for uninterrupted AI operations. Pelosi’s continued holding of Vistra shares reinforces a bullish outlook.

Sponsored Segment: Serena Therapeutics (SERA) – Revolutionizing Parkinson’s Disease Treatment

Serena Therapeutics (ticker: SERA) is a biotechnology company addressing a critical limitation in Parkinson’s disease treatment: the challenges associated with Apomorphine delivery. While Apomorphine is highly effective, its poor oral bioavailability necessitates injection or continuous pump infusion. Pump therapy, while effective, is plagued by issues like skin nodules, irritation, and patient discomfort, leading to high discontinuation rates.

Serena’s SR252 is a long-acting Apomorphine formulation delivered via twice-weekly subcutaneous injection, eliminating the need for pumps and daily needle changes. The FDA cleared Serena’s Investigational New Drug (IND) application on January 28th, 2026, enabling a Phase 1B registrational clinical study. The company is pursuing a 505(b)(2) regulatory pathway, leveraging existing data to expedite approval.

Key Personnel & Technology:

• CEO Steve Ledger: 35+ years of biotech experience.
• Dr. Greg Bailey (Board Member): Co-founder of Juvalence, successful biotech investor.
• PZ Platform Technology: Licensed from Pfizer, used in drugs with over $100 billion in cumulative sales.
• Lipid Nanoparticle Technology: Validated by mRNA vaccine success.

Market Opportunity: The global Parkinson’s disease market is projected to reach $7.58 billion by 2030. The target segment of advanced patients with motor fluctuations represents approximately 180,000 individuals in the US and Europe.

Risks: Clinical-stage biotechnology carries inherent risks, including potential trial failures and regulatory hurdles. However, Serena’s innovative approach, experienced leadership, and strategic partnerships position it for potential success.

Conclusion

Nancy Pelosi’s recent trading activity reveals a sophisticated investment strategy focused on identifying opportunities at the intersection of technology, policy, and infrastructure. Her investments in AI-driven companies, established tech giants, and the energy sector powering AI data centers demonstrate a forward-looking perspective. The inclusion of a defensive asset like Alliance Bernstein suggests a focus on portfolio diversification and income generation. The spotlight on Vistra Corp highlights the often-overlooked importance of infrastructure in the AI revolution. Finally, the sponsored segment on Serena Therapeutics showcases a promising biotechnology company addressing a significant unmet need in Parkinson’s disease treatment. Investors should conduct thorough due diligence before making any investment decisions, but Pelosi’s trades offer valuable insights into potential growth areas and emerging trends.